1 / 10

Eylea Industry Analysis for US, 5EU and Japan

The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan).

peter_dj
Download Presentation

Eylea Industry Analysis for US, 5EU and Japan

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022byGlobalData Explore all reports for “ Diabetes Therapeutics” market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/diabetes-therapeutics . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  2. Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 The report “Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022″ by GlobalDatais now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022“ in subject line and your contact details to purchase this report or get your questions answered. The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. Buy a copy of this report byGlobalData @ http://www.rnrmarketresearch.com/contacts/purchase?rname=147161 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  3. Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 Eylea is a fusion protein consisting of VEGF-binding portions. It is specifically designed to bind to all isoforms of VEGF-A, VEGF-B and placental growth factor (PGF), leading to their removal from circulation. Decrease in VEGF-A levels causes a decrease in macular edema by restricting the growth of new blood vessels. Scope Overview of MCD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Eylea including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Eylea for the top seven countries from 2012 to 2022. Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  4. Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for MCD Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Eylea performance Obtain sales forecast for Eylea from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan) Complete report spread across 75pages available @http://www.rnrmarketresearch.com/eylea-microvascular-complications-of-diabetes-forecast-and-market-analysis-to-2022-market-report.html . Read more on “Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022” reportbelow. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  5. Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 Table Of Contents 1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 9 2 Introduction 102.1 Catalyst 102.2 Related Reports 11 3 Disease Overview 133.1 Etiology and Pathophysiology 153.1.1 Diabetic Nephropathy 153.1.2 Diabetic Retinopathy 173.1.3 Diabetic Neuropathy 183.2 Prognosis 193.3 Quality of Life 203.4 Symptoms 21 4 Disease Management 224.1 Treatment Overview 224.1.1 Diagnosis and Referrals 224.1.2 Screening 244.1.3 Treatment Guidelines 25 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  6. Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 5 Competitive Assessment 335.1 Overview 335.2 Strategic Competitor Assessment 34 6 Opportunity and Unmet Need 386.1 Overview 386.2 Unmet Needs 396.2.1 Unified Treatment for the Microvascular Complications of Diabetes 396.2.2 Optimization of Personalized Therapy in the Microvascular Complications of Diabetes 396.2.3 Treatment for Diabetic Nephropathy that Would Prevent ESRD 416.2.4 Cardio- and Renoprotective Therapy for Diabetic Nephropathy 426.2.5 Efficient Therapy for Retinopathy 436.2.6 Convenient Administration in Diabetic Retinopathy Treatment 436.2.7 Treatment for Diabetic Neuropathy 446.3 Unmet Needs Gap Analysis 456.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 476.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 476.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 486.7 Opportunity: Topical Treatment for Diabetic Retinopathy 48 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  7. Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 7 Pipeline Assessment 507.1 Overview 507.2 Promising Drugs in Clinical Development 52 8 Eylea (aflibercept) 548.1 Overview 548.2 Efficacy 568.3 Safety 578.4 Dosing and Formulation 578.5 Potential Clinical Positioning 578.6 Potential Commercial Positioning 588.7 Pricing and Reimbursement 588.8 SWOT Analysis 598.9 Forecast 59 9 Appendix 619.1 Bibliography 619.2 Abbreviations 659.3 Methodology 679.4 Forecasting Methodology 679.4.1 Diagnosed Patients 679.4.2 Percent Drug-Treated Patients 689.4.3 General Pricing Assumptions 689.4.4 Generic Erosion 699.4.5 Pricing of Pipeline Agents 69 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  8. Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 List of Tables Table 1: Risk Factors for MCD 15Table 2: Symptoms of MCD 21Table 3: Diagnostic Tests and Typical Criteria for MCD 23Table 4: Treatment Guidelines for MCD 26Table 5: Most Prescribed Drugs for MCD by Class in the 7MM, 2012 29Table 6: Leading Drug Treatments for MCD, 2013 36Table 7: Overall Unmet Needs - Current Level of Attainment 38Table 8: Clinical Unmet Needs in MCD - Gap Analysis, 2012 46Table 9: MCD - Phase Pipeline, 2013 52Table 10: Comparison of Drugs in Development for MCD, 2013 53Table 11: Product Profile - Eylea 55Table 12: Eylea SWOT Analysis, 2013 59Table 13: Global Sales Forecasts ($m) for Eylea, 2012-2022 60Table 14: Number of High-Prescribing Physicians Surveyed 71 List of Figures Figure 1: Potential Mechanisms of Diabetes-Induced Microvascular Complications 14Figure 2: General Treatment Algorithms for MCD 27Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in MCD, 2012-2022 53 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  9. Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 For further information on “Eylea (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘Diabetes Therapeutics’ market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/diabetes-therapeutics . Contact: sales@rnrmarketresearch.com OR Call +1 888 391 5441. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  10. Eloctate (Hemophilia A and B) – Forecast and Market Analysis to 2022 For more details contact Mr. PriyankTiwari:sales@rnrmarketresearch.com/ +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnR  Market Research library has syndicated reports by leading market research  publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

More Related